TheraRadar
Clinical-Stage Companies / Sol-Gel Technologies

Sol-Gel Technologies

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 3/17/2024

15
Total Trials
9
Phase 3
4
Phase 2
1
Recruiting
173
Score

Pipeline by Phase

Phase 3
9
Phase 2
4
Phase 1
2

Therapeutic Focus

Papulopustular Rosacea Acne Vulgaris Basal Cell Nevus Syndrome Gorlin Syndrome Recurrent Basal Cell Carcinoma

Clinical Trials (15)

NCT06050122 Phase 3 ACTIVE NOT RECRUITING

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Started: 3/17/2024

NCT04308395 Phase 3 TERMINATED

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Started: 6/3/2020

NCT03703310 Phase 3 COMPLETED

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Started: 2/19/2019

NCT03761784 Phase 3 COMPLETED

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

Started: 12/21/2018

NCT03761810 Phase 3 COMPLETED

A Study of S6G5T3 in the Treatment of Acne Vulgaris

Started: 12/14/2018

NCT03564119 Phase 3 COMPLETED

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

Started: 6/21/2018

NCT03564145 Phase 3 TERMINATED

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Started: 9/12/2018

NCT03448939 Phase 3 COMPLETED

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Started: 6/18/2018

NCT03727074 Phase 3 COMPLETED

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

Started: 12/21/2018

NCT04155190 Phase 2 TERMINATED

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Started: 12/20/2019

NCT02842021 Phase 2 TERMINATED

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Started: 9/1/2016

NCT02661958 Phase 2 COMPLETED

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

Started: 5/1/2016

NCT00940992 Phase 2 COMPLETED

A Study of DER 45-EV Gel to Treat Rosacea

Started: 1/1/2012

NCT05675501 Phase 1 COMPLETED

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

Started: 6/10/2020

NCT04059523 Phase 1 COMPLETED

MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

Started: 6/27/2019

Drug Candidates

Patidegib Topical Gel Patidegib Topical Gel with no active patidegib Patidegib Topical Gel, 2% Patidegib Topical Gel, Vehicle Encapsulated Benzoyl Peroxide Cream S6G5T-3 S6G5T-8 S5G4T-1 S5G4T-2 S2G6T-1
Activity Status: Stale
Last Trial Started: 3/17/2024
Last Trial Ended: 7/15/2021
Trials (12 months): 0
Completed Trials: 10
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.